FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
49 letters match. Newest first.
-
BiologicsBeaute Bounty
FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.
High risk -
BiologicsBlue Horizon International, LLC
FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.
High risk -
BiologicsCentral Coast Multispecialty Medical Group, Inc.
FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.
High risk -
BiologicsConceive Fertility Center
FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.
High risk -
BiologicsLouisville Reproductive Center
Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.
High risk -
BiologicsGreen Valley Fertility Partners
FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.
High risk -
BiologicsMicrovascular Tissue, Inc.
FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.
High risk -
BiologicsCelularity, Inc
FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.
High risk -
BiologicsBioXtek LLC
FDA says BioXtek's amniotic membrane products are unapproved new drugs and unlicensed biological products.
High risk -
BiologicsLux Therapeutics LLC dba Ponya Therapeutics LLC
FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.
High risk -
BiologicsNew Life Medical Services, LLC
FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.
High risk -
BiologicsCellebration LLC
FDA warns Cellebration LLC over unapproved cord-blood cellular products and refusal to provide requested records.
High risk -
BiologicsNuVida Medical LLC
FDA says NuVida Medical sells unapproved, unlicensed tissue products for non-homologous wound care uses.
High risk -
BiologicsPlatinum Biologics LLC
FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.
High risk -
BiologicsInnate Healthcare Institute
FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.
High risk -
BiologicsInVia Fertility Specialists, PLLC
FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.
High risk -
BiologicsSkye Biologics Holdings LLC
FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.
High risk -
BiologicsSperm Bank, Inc. dba Fertility Center of California
FDA warned Sperm Bank, Inc. dba Fertility Center of California over donor semen released without required infectious-disease testing and screening.
High risk -
BiologicsBioStem Life Sciences
FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.
High risk -
BiologicsChara Biologics, Inc.
FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.
High risk -
BiologicsEvolutionary Biologics Inc.
FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.
High risk -
BiologicsPinnacle Transplant Technologies, LLC
FDA warns Pinnacle Transplant Technologies over unapproved injectable amniotic products and sterility CGMP failures.
High risk -
BiologicsAmnio Technology, LLC
FDA warned Amnio Technology over unapproved injectable amniotic products and serious manufacturing deviations at its Phoenix facility.
High risk -
BiologicsMother Stem Institute, Corp.
FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.
High risk -
BiologicsBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.
FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.
High risk -
BiologicsNew Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank
FDA warns New Mexico eye bank over distributing eye tissue from two donors with sepsis.
High risk -
BiologicsIndiana Lions Eye Bank, Inc. dba VisionFirst Indiana Lions Eye Bank
Indiana Lions Eye Bank distributed ocular tissue from donors with sepsis after failing to screen them as ineligible.
High risk -
BiologicsNeobiosis, LLC
FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.
High risk -
BiologicsAkan Biosciences, Inc.
FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.
High risk -
BiologicsWashington Fertility Center
FDA warned Washington Fertility Center about incomplete donor eligibility screening and testing for oocytes, semen, and embryos.
High risk -
BiologicsMiMedx Group, Inc.
FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.
High risk -
BiologicsSignature Biologics, LLC
FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
High risk -
BiologicsRenatiLabs Inc.
RenatiLabs marketed WJMAX, a human umbilical cord-derived biologic, without a license and released a lot that failed sterility testing.
High risk -
BiologicsStratus Biosystems, LLC dba CellGenuity Regenerative Science
FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.
High risk -
BiologicsThe New Hope Center for Reproductive Medicine
FDA warns Virginia Beach fertility center over incomplete donor screening and testing for reproductive tissue.
High risk -
BiologicsRow1 Inc. dba Regenative Labs
FDA warned Regenative Labs that its umbilical cord products are unlicensed drugs, made under serious sterility and manufacturing failures.
High risk -
BiologicsMark S. Denker, M.D., PA dba Palm Beach Fertility Center
FDA warns Boca Raton fertility center over failures to screen sperm and egg donors for infectious disease risk.
High risk -
BiologicsCryos International USA LLC
Cryos International USA released and distributed anonymous donor semen without required infectious disease testing and quarantine.
High risk -
BiologicsInvitrx Therapeutics, Inc.
Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.
High risk -
BiologicsBioLab Sciences, Inc.
FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.
High risk -
BiologicsVitti Labs, LLC
FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.
High risk -
BiologicsZhang Medical P.C. dba New Hope Fertility Center
New Hope Fertility Center failed to properly screen and test oocyte and semen donors for communicable diseases, FDA says.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
BiologicsOsteoLife Biomedical I LLC
FDA warned OsteoLife Biomedical over unvalidated processing and microbial contamination of human bone tissue products, including distributed batches.
High risk -
BiologicsSmart Surgical, Inc dba Burst Biologics
Burst Biologics distributed unapproved umbilical cord blood products as drugs while failing sterility and donor-screening rules.
High risk -
BiologicsCooper Institute
FDA warned Houston fertility clinic Cooper Institute that it failed to test and screen oocyte donors for infectious diseases.
High risk -
BiologicsSurgenex LLC
FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.
High risk -
BiologicsUtah Cord Bank LLC dba Utah Cell Bank
Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.
High risk -
BiologicsUtah Cord Bank LLC
FDA cited Utah Cord Bank for unvalidated cord blood processing, missing environmental monitoring, procedures, and records after a February 2021 inspection.
High risk